FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

It’s an important nod for Novartis, which has bet big on the radiopharmaceutical industry. The approval nearly doubles the eligible patient population for Pluvicto.